Fortress Biotech, Inc. FBIO 深 沪
等待开盘 02-19 09:30:00 美东时间
3.45
-0.050
-1.43%
华盛通- 最 高4.53
- 今 开3.50
- 成交量 19.07万股
- 最 低 2.91
- 昨 收 3.50
- 总市值 36.92万
- 52周最高 4.53
- 市盈率 静 --
- 换手率 178.19%
- 52周最低 1.325
- 委 比 80.66%
- 总股本 0.00亿
- 历史最高 12.70
- 量 比 0.48
- 振 幅 46.29%
- 历史最低 0.2806
- 每 手 1
- 风险率 0.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics
Fortress Biotech subsidiary Checkpoint Therapeutics was acquired by Sun Pharma for $4.10 per share, with potential for an additional $0.70 via CVR. Fortress will receive ~$28 million and a 2.5% royalty on UNLOXCYT sales, plus up to $4.8 million upon CVR achievement. UNLOXCYT, the first FDA-approved PD-L1 blocker for advanced cutaneous squamous cell carcinoma, is now under Sun Pharma’s global commercialization.
2025-05-30 14:47
Roth MKM Reiterates Buy on Fortress Biotech, Raises Price Target to $16
Roth MKM analyst Jason Wittes reiterates Fortress Biotech (NASDAQ:FBIO) with a Buy and raises the price target from $15 to $16.
2025-03-11 22:49
India-Based Sun Pharma To Buy US Cancer Firm Checkpoint Therapeutics: Details
Sun Pharma to acquire Checkpoint Therapeutics for $4.10 per share, with potential CVR. FDA approves Unloxcyt, the first PD-L1 blocker for advanced cSCC.
2025-03-10 23:08
Why Fortress Biotech (FBIO) Stock Is Getting Hammered
Fortress Biotech shares are trading lower by 20% Friday afternoon. The company announced the pricing of a $8 million registered direct offering and concurrent private placements.
2024-09-21 00:15
